Clinical Trial Update: Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) [Phase 1]

View source ↗

Summary

This update reports Phase 1 safety findings for MB-CART2019.1 in patients with B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• MB-CART2019.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED